每周一次与每3周一次顺铂联合同步放疗治疗头颈癌的3期随机研究长期更新
这项3期开放标签非劣效研究纳入300例局部晚期头颈鳞癌患者,随机接受每3周一次顺铂100 mg/m²或每周一次顺铂30 mg/m²联合同步根治性放疗。中位随访6.91年,每3周组局部区域控制显著优于每周组(HR=1.44,P=.034),5年总生存两组无显著差异(P=.19),高剂量顺铂组听力障碍更常见。
要点
- 每3周一次顺铂100 mg/m²组局部区域控制优于每周一次30 mg/m²组,HR=1.44(95%CI 1.03-2.03),P=.034
- 5年总生存两组无显著差异:每周组43.60% vs 每3周组50.55%,P=.19
- 除听力障碍在高剂量顺铂组更常见外,两组任何级别及≥3级晚期不良事件无差异
核心结论
- 长期随访证实,每3周一次顺铂100 mg/m²联合同步根治性放疗治疗局部晚期头颈鳞癌,局部区域控制优于每周一次顺铂30 mg/m²,应继续作为标准治疗选择之一。
研究设计与样本
- 3期开放标签非劣效研究,2013年至2017年间纳入300例局部晚期头颈鳞癌患者,随机接受每3周一次顺铂100 mg/m²或每周一次顺铂30 mg/m²联合同步放疗。
- 主要终点为局部区域控制,次要终点为总生存、无进展生存和晚期不良事件。
主要发现
- 中位随访6.91年(95%CI 6.12-7.36)。
- 每周一次顺铂组2年和5年局部区域控制率分别为58.75%(95%CI 51.08-67.58)和48.09%(95%CI 40.26-57.43),每3周一次顺铂组分别为73.95%(95%CI 66.93-81.70)和56.76%(95%CI 48.46-66.48),HR=1.44(95%CI 1.03-2.03),P=.034。
- 5年总生存率每周一次顺铂组为43.60%(95%CI 36.29-52.37),每3周一次顺铂组为50.55%(95%CI 43.06-59.35),P=.19。
- 两组任何级别或≥3级晚期不良事件无差异,但听力障碍在接受高剂量顺铂的患者中显著更常见。
临床怎么用
- 作者结论认为,每3周一次顺铂100 mg/m²联合同步根治性放疗应继续作为局部晚期头颈鳞癌的标准治疗选择之一。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In the weekly-3-weekly study, cisplatin at 100 mg/m2 once-every-3-weeks led to superior locoregional control compared with cisplatin 30 mg/m2 once-a-week in combination with radical radiation for locally advanced head and neck squamous cell carcinoma (LAHNSCC). We report the updated analysis of the study. METHODS AND MATERIALS: In this phase 3 open-label noninferiority study conducted between 2013 and 2017, 300 patients with LAHNSCC were randomly assigned to receive cisplatin 100 mg/m2 once-in-every-weeks or cisplatin 30 mg/m2 once-a-week, concurrently with radiation. The primary endpoint was locoregional control. Secondary outcomes were overall survival, progression-free survival, and late adverse events. RESULTS: The median follow-up was 6.91 years (95% CI, 6.12-7.36). The updated 2-year and 5-year locoregional control rates for the once-a-week cisplatin arm were 58.75% (95% CI, 51.08-67.58) and 48.09% (95% CI, 40.26-57.43), whereas for the once-every-3-weeks, cisplatin arm were 73.95% (95% CI, 66.93-81.70) and 56.76% (95% CI, 48.46-66.48), respectively, hazard ratio = 1.44 (95% CI, 1.03-2.03), P = .034. The 5-year overall survival was 43.60% (95% CI, 36.29-52.37) in the once-a-week cisplatin arm and 50.55% (95% CI, 43.06-59.35) in the once-every-3-weeks cisplatin arm; P = .19. There was no difference in any grade or grade ≥3 late adverse events between the 2 arms, except for hearing dysfunction, which was significantly more common in patients who received high-dose cisplatin. CONCLUSIONS: Long-term follow-up confirms that cisplatin at 100 mg/m2 administered once-every-3-weeks concurrently with radical radiation for LAHNSCC leads to superior locoregional control compared with cisplatin 30 mg/m2 once-a-week and should remain one of the standard treatment options.
引用
- Noronha V, Patil V, Menon N, et al. Long-Term Update of a Phase 3 Randomized Study Comparing Once-a-Week Versus Once-Every-3-Weeks Cisplatin Along With Radiation in Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 39074566. doi:10.1016/j.ijrobp.2024.07.2315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。